Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CohBar, Inc.CWBR · Entity 124935 | Director | May 31, 2019 | June 04, 2019 |
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director | June 14, 2024 | June 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CohBar, Inc.
Report date May 31, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2029-05-31 | Direct | 24,000 |
Reported balance
After 2019-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-31 · Grant · Acquired 24,000 · Balance 24,000 F1: Shares subject to the option vested immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vested immediately upon grant.
Transcode Therapeutics, Inc.
Report date June 14, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2034-06-13 | Direct | 70,000 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 70,000 · Balance 70,000 F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adhera Therapeutics, Inc.
Report date May 02, 2018 · Filed May 04, 2018
Section 16 reporting ended · disclosed 2018-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2023-05-02 | Direct | 80,000 |
Reported balance
After 2018-05-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-02 · Grant · Acquired 80,000 · Balance 80,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 18, 2024 16:15 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-24-072817 · tm2417512-1_4seq1.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 20:06 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-23-062812 · tm2316383-1_4seq1.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time. Read SEC document |
| May 10, 2023 Filed May 10, 2023 18:10 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-23-058580 · tm2315294-1_4seq1.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 10, 2024 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 22, 2022 Filed Jun 22, 2022 20:27 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001104659-22-073636 · tm2219203d3_4seq1.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 08:36 UTC | CohBar, Inc. CWBR · Entity 124935 | GrantStock Options (Right to buy) · Derivative | 24,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001213900-19-010010 · ownership.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: Shares subject to the option vested immediately upon grant. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:14 UTC | CohBar, Inc. CWBR · Entity 124935 | GrantStock Options (right to buy) · Derivative | 96,000 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001209191-18-061737 · doc4.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director · Interim Chief Executive Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2028-12-06 F1 · derivative.exercise_date: Shares subject to the option shall vest in 4 successive monthly installments beginning December 7, 2018. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 18:07 UTC | CohBar, Inc. CWBR · Entity 124935 | GrantStock Options (right to buy) · Derivative | 200,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001209191-18-036482 · doc4.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Comon Stock · 200,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: Shares subject to the option shall vest in 48 successive monthly installments beginning June 6, 2018. Read SEC document |
| May 02, 2018 Filed May 4, 2018 17:00 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 80,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-18-006281 · form4.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: common stock · 80,000 shares Expires 2023-05-02 Read SEC document |
| January 03, 2018 Filed Jan 3, 2018 18:41 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 3,800 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001587074-18-000002 · primary_doc.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: common stock · 3,800 shares Expires 2023-01-03 F1 · derivative.exercise_date: Options to purchase 1,900 shares of common stock are exercisable beginning on January 3, 2018, and options to purchase 1,900 shares of common stock are exercisable beginning on January 3, 2019. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 18:17 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 81,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001493152-17-000141 · form4.xml · derivative · entry 1 Calais Philippe · CIK 0001693728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: common stock · 81,000 shares Expires 2022-01-03 F1 · derivative.exercise_date: Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.